Lower circulating endocannabinoid levels in children with autism spectrum disorder.
2-arachidonoylglycerol
Anandamide
Arachidonic acid
Autism spectrum disorder
Biomarkers
Cannabinoids
Endocannabinoid system
N-arachidonoylethanolamine
N-oleoylethanolamine
N-palmitoylethanolamine
Journal
Molecular autism
ISSN: 2040-2392
Titre abrégé: Mol Autism
Pays: England
ID NLM: 101534222
Informations de publication
Date de publication:
2019
2019
Historique:
received:
14
09
2018
accepted:
18
01
2019
entrez:
8
2
2019
pubmed:
8
2
2019
medline:
12
4
2019
Statut:
epublish
Résumé
The endocannabinoid system (ECS) is a major regulator of synaptic plasticity and neuromodulation. Alterations of the ECS have been demonstrated in several animal models of autism spectrum disorder (ASD). In some of these models, activating the ECS rescued the social deficits. Evidence for dysregulations of the ECS in human ASD are emerging, but comprehensive assessments and correlations with disease characteristics have not been reported yet. Serum levels of the main endocannabinoids, Children with ASD had lower levels (pmol/mL, mean ± SEM) of AEA (0.722 ± 0.045 vs. 1.252 ± 0.072, We found lower serum levels of AEA, PEA, and OEA in children with ASD. Further studies are needed to determine whether circulating endocannabinoid levels can be used as stratification biomarkers that identify clinically significant subgroups within the autism spectrum and if they reflect lower endocannabinoid "tone" in the brain, as found in animal models of ASD.
Sections du résumé
Background
The endocannabinoid system (ECS) is a major regulator of synaptic plasticity and neuromodulation. Alterations of the ECS have been demonstrated in several animal models of autism spectrum disorder (ASD). In some of these models, activating the ECS rescued the social deficits. Evidence for dysregulations of the ECS in human ASD are emerging, but comprehensive assessments and correlations with disease characteristics have not been reported yet.
Methods
Serum levels of the main endocannabinoids,
Results
Children with ASD had lower levels (pmol/mL, mean ± SEM) of AEA (0.722 ± 0.045 vs. 1.252 ± 0.072,
Conclusions
We found lower serum levels of AEA, PEA, and OEA in children with ASD. Further studies are needed to determine whether circulating endocannabinoid levels can be used as stratification biomarkers that identify clinically significant subgroups within the autism spectrum and if they reflect lower endocannabinoid "tone" in the brain, as found in animal models of ASD.
Identifiants
pubmed: 30728928
doi: 10.1186/s13229-019-0256-6
pii: 256
pmc: PMC6354384
doi:
Substances chimiques
Biomarkers
0
Endocannabinoids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2Déclaration de conflit d'intérêts
All research procedures were approved by the Shaare Zedek Medical Center Review Board and Israeli Ministry of Health prior to participant enrollment. Participants’ parents provided written consent prior to initiation of any experimental procedures, and written assent was obtained from participants when appropriate.Not applicable.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Références
Lancet. 2018 Mar 17;391(10125):1085-1096
pubmed: 29395273
Handb Exp Pharmacol. 2015;231:285-316
pubmed: 26408165
Eur J Neurosci. 2006 Apr;23(7):1944-8
pubmed: 16623851
Obesity (Silver Spring). 2017 Jan;25(1):94-101
pubmed: 27863097
Brain Behav Immun. 2016 Nov;58:237-247
pubmed: 27453335
Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Feb;1862(2):255-267
pubmed: 27871881
Eur Neuropsychopharmacol. 2008 Oct;18(10):751-9
pubmed: 18579347
Mol Psychiatry. 2013 Jul;18(7):813-23
pubmed: 22688188
Cannabis Cannabinoid Res. 2016 Feb 01;1(1):81-89
pubmed: 28861483
Psychol Res Behav Manag. 2012;5:51-6
pubmed: 22715318
Genes (Basel). 2016 Aug 31;7(9):
pubmed: 27589806
Autism. 2013 Sep;17(5):608-22
pubmed: 22987887
J Neurosci. 2008 Mar 5;28(10):2313-9
pubmed: 18322078
Int J Mol Sci. 2017 Sep 07;18(9):
pubmed: 28880200
Br J Pharmacol. 2016 Mar;173(5):815-25
pubmed: 26497782
J Autism Dev Disord. 2000 Jun;30(3):205-23
pubmed: 11055457
Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):14084-9
pubmed: 26504214
Neurotherapeutics. 2015 Oct;12(4):692-8
pubmed: 26271952
Nature. 1970 May 23;226(5247):701-4
pubmed: 5443246
Neuron. 2013 May 8;78(3):498-509
pubmed: 23583622
Neuropsychopharmacology. 2013 Aug;38(9):1816-24
pubmed: 23563893
J Autism Dev Disord. 1980 Mar;10(1):91-103
pubmed: 6927682
Neuropharmacology. 2008 Jan;54(1):141-50
pubmed: 17709120
Ment Retard Dev Disabil Res Rev. 2000;6(4):300-8
pubmed: 11107195
Epilepsy Behav. 2017 May;70(Pt B):319-327
pubmed: 28190698
Neuroscience. 1997 Mar;77(2):299-318
pubmed: 9472392
Am J Psychiatry. 1976 Sep;133(9):1029-33
pubmed: 961922
J Neurosci. 2012 Oct 24;32(43):14899-908
pubmed: 23100412
Br J Pharmacol. 2018 Sep;175(18):3699-3712
pubmed: 29968249
Mol Autism. 2018 Mar 12;9:18
pubmed: 29564080
Neuropsychopharmacology. 2018 Jan;43(1):155-172
pubmed: 28653665
Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):11229-11234
pubmed: 28973916
N Engl J Med. 2018 May 17;378(20):1888-1897
pubmed: 29768152
J Biol Chem. 2015 Apr 3;290(14):8711-21
pubmed: 25666611
J Psychopharmacol. 2012 Oct;26(10):1317-32
pubmed: 22495620
Autism. 2016 Jul;20(5):528-37
pubmed: 26187059
N Engl J Med. 2017 May 25;376(21):2011-2020
pubmed: 28538134
Transl Psychiatry. 2016 Sep 27;6(9):e902
pubmed: 27676443
Epilepsy Res. 2016 Dec;128:35-42
pubmed: 27810514
Pharmacol Res. 2016 Nov;113(Pt A):228-235
pubmed: 27592249
Neurology. 2001 Nov 13;57(9):1618-28
pubmed: 11706102
J Autism Dev Disord. 2012 Apr;42(4):566-74
pubmed: 21556967
Am J Drug Alcohol Abuse. 1977;4(2):251-5
pubmed: 612199
Behav Brain Res. 2013 Jul 15;249:124-32
pubmed: 23643692
J Autism Dev Disord. 2013 Nov;43(11):2686-95
pubmed: 23585028
Mol Autism. 2011 Jun 29;2(1):10
pubmed: 21714860
Nat Commun. 2012;3:1080
pubmed: 23011134
Epilepsy Behav. 2015 Jun;47:191-201
pubmed: 25900226
Nat Med. 2013 May;19(5):603-7
pubmed: 23542787